Increasing evidence indicates that mutations in the BRAF oncogene are not only tied to a poorer prognosis but also correlate with reduced efficacy of anti-epidermal growth factor receptor antibodies in treating metastatic colorectal cancer (mCRC) [15]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.